Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients.

Because of advances in immunological technology for detecting a very small number of blood CTL cells, clinicians have been able to monitor cellular immunity against CMV and evaluate the status of CMV infections in highly advanced cancer patients or transplant recipients. Our previous study using healthy volunteer PBLs revealed a significant increase in CMV HLA-A24 tetramer+ CTLs after stimulation in vitro with autologous DCs. However, the efficiency of CMV A24 peptide-specific CTL expansion in highly advanced cancer patients has yet to be studied in detail. In the present study, we tried to characterize and expand HLA-A*2402 CMVpp65 peptide (QYDPVAALF)-specific tetramer+ CTLs from HLA-A*2402+ metastatic melanoma patients, and eventually demonstrated that expansion efficiency was closely related to both post-stimulation CMV tetramer frequency and anti-CMV IgG titer. This is a novel finding regarding in vitro CMVpp65-A24 peptide-specific CTL expansion based on metastatic cancer patient-derived PBLs. Interestingly, the current results using metastatic melanoma PBLs showed a much higher frequency of CMVpp65-A24 tetramer+ CTLs and expansion efficiency than in healthy volunteers. Finally, we were successful in cloning CMVpp65 HLA-A24 peptide-specific TCR cDNAs from in vitro expanded CTL lines derived from melanoma patients. Additionally, CMVpp65 HLA-A24 peptide-specific TCR cDNA was transduced into naive T cells from patients and functionally reconstructed. The results showed that cloned CMV-specific TCR genes were efficient in reconstituting specific anti-CMV activity and might be good tools for adoptive immunotherapy against CMV infections.

[1]  D. Stroncek,et al.  Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. , 2006, Experimental hematology.

[2]  森田 百合子.  Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A[*]02 or HLA-A[*]24 phenotype undergoing hematopoietic stem cell transplantation , 2005 .

[3]  Y. Kanda,et al.  Reconstitution of HLA-A*2402-Restricted Cytomegalovirus-Specific T-Cells Following Stem Cell Transplantation , 2004, International journal of hematology.

[4]  K. Kuzushima,et al.  Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes. , 2004, Cytotherapy.

[5]  K. Yamaguchi,et al.  Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. , 2004, Anticancer research.

[6]  M. Tanimoto,et al.  Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. , 2004, Blood.

[7]  F. Marincola,et al.  The matrix protein pp65341‐350: a peptide that induces ex vivo stimulation and in vitro expansion of CMV‐specific CD8+ T cells in subjects bearing either HLA‐A*2402 or A*0101 allele , 2003, Transfusion.

[8]  Rajiv Khanna,et al.  Promiscuous CTL Recognition of Viral Epitopes on Multiple Human Leukocyte Antigens: Biological Validation of the Proposed HLA A24 Supertype 1 , 2003, The Journal of Immunology.

[9]  M. Essand,et al.  Ex vivo stimulation of cytomegalovirus (CMV)‐specific T cells using CMV pp65‐modified dendritic cells as stimulators , 2003, British journal of haematology.

[10]  O. Korsgren,et al.  Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment , 2003, Clinical and experimental immunology.

[11]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[12]  K. Yamaguchi,et al.  Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. , 2002, Immunology letters.

[13]  H. Einsele,et al.  Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. , 2002, Cytotherapy.

[14]  A. Barrett,et al.  Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors. , 2002, Cytotherapy.

[15]  K. Itoh,et al.  Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. , 2001, Viral immunology.

[16]  S. Grace,et al.  Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. , 2001, The Journal of infectious diseases.

[17]  T. Tsurumi,et al.  Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. , 2001, Blood.

[18]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[19]  N. Hensel,et al.  Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. , 2001, Blood.

[20]  Q. Sun,et al.  A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. , 2000, Human gene therapy.

[21]  C. Tournay,et al.  Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. , 2000, Transplantation.

[22]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[23]  S. Forman,et al.  Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? , 1994, Blood.

[24]  R. Chaisson,et al.  Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.

[25]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.